- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04976322
Une étude pour évaluer l'innocuité et la tolérabilité du dapirolizumab pegol chez les participants à l'étude atteints de lupus érythémateux disséminé
Une étude d'extension multicentrique et ouverte pour évaluer l'innocuité et la tolérabilité à long terme du traitement par le dapirolizumab pegol chez les participants à l'étude atteints de lupus érythémateux disséminé
The purpose of this study is to evaluate long-term safety and tolerability of dapirolizumab pegol treatment.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
-
Cologne, Allemagne
- Sl0046 40386
-
Freiburg im Breisgau, Allemagne
- Sl0046 40072
-
Herne, Allemagne
- Sl0046 40027
-
Leipzig, Allemagne
- Sl0046 40078
-
Tübingen, Allemagne
- Sl0046 40402
-
Vogelsang-gommern, Allemagne
- Sl0046 40715
-
-
-
-
-
Buenos Aires, Argentine
- Sl0046 60002
-
Mendoza, Argentine
- Sl0046 60029
-
Quilmes, Argentine
- Sl0046 60003
-
Quilmes, Argentine
- Sl0046 60022
-
San Juan, Argentine
- Sl0046 60011
-
San Miguel de Tucumán, Argentine
- Sl0046 60014
-
-
-
-
-
Brussels, Belgique
- Sl0046 40123
-
-
-
-
-
Plovdiv, Bulgarie
- Sl0046 40189
-
Sofia, Bulgarie
- Sl0046 40380
-
-
-
-
-
Calgary, Canada
- Sl0046 50374
-
Edmonton AB, Canada
- Sl0046 50337
-
Rimouski, Canada
- Sl0046 50259
-
Toronto, Canada
- Sl0046 50045
-
-
-
-
-
Santiago, Chili
- Sl0046 60018
-
Santiago, Chili
- Sl0046 60015
-
-
-
-
-
Beijing, Chine
- Sl0046 20128
-
Changchun, Chine
- Sl0046 20291
-
Guangzhou, Chine
- Sl0046 20019
-
Guilin, Chine
- Sl0046 20290
-
Shanghai, Chine
- Sl0046 20020
-
Shantou, Chine
- Sl0046 20346
-
Suzhou, Chine
- Sl0046 20204
-
Tianjin, Chine
- Sl0046 20136
-
Wenzhou, Chine
- Sl0046 20025
-
Wuhan, Chine
- Sl0046 20180
-
Yangzhou, Chine
- Sl0046 20273
-
Zhengzhou, Chine
- Sl0046 20132
-
-
-
-
-
Barranquilla, Colombie
- Sl0046 60013
-
Barranquilla, Colombie
- Sl0046 60019
-
Bogotá, Colombie
- Sl0046 60006
-
Bogotá, Colombie
- Sl0046 60027
-
Bucaramanga, Colombie
- Sl0046 60016
-
Chía, Colombie
- Sl0046 60007
-
Montería, Colombie
- Sl0046 60031
-
-
-
-
-
Incheon, Corée du Sud
- Sl0046 20108
-
Seoul, Corée du Sud
- Sl0046 20104
-
-
-
-
-
Barcelona, Espagne
- Sl0046 40160
-
Málaga, Espagne
- Sl0046 40341
-
Sabadell, Espagne
- Sl0046 40101
-
Vigo, Espagne
- Sl0046 40099
-
-
-
-
-
Athens, Grèce
- Sl0046 40378
-
Athens, Grèce
- Sl0046 40501
-
Crete, Grèce
- Sl0046 40377
-
Larissa, Grèce
- Sl0046 40507
-
-
-
-
-
Budapest, Hongrie
- Sl0046 40412
-
Debrecen, Hongrie
- Sl0046 40411
-
Szeged, Hongrie
- Sl0046 40031
-
Székesfehérvár, Hongrie
- Sl0046 40499
-
-
-
-
-
Catania, Italie
- Sl0046 40084
-
Milan, Italie
- Sl0046 40448
-
-
-
-
-
Nagoya, Japon
- Sl0046 20287
-
-
-
-
-
Chihuahua City, Mexique
- Sl0046 50317
-
Cuernavaca, Mexique
- Sl0046 50250
-
Guadalajara, Mexique
- Sl0046 50249
-
León, Mexique
- Sl0046 50271
-
Monterrey, Mexique
- Sl0046 50251
-
Mérida, Mexique
- Sl0046 50252
-
-
-
-
-
Davao City, Philippines
- Sl0046 20182
-
Makati, Philippines
- Sl0046 20181
-
-
-
-
-
Bialystok, Pologne
- Sl0046 40482
-
Bydgoszcz, Pologne
- Sl0046 40119
-
Katowice, Pologne
- Sl0046 40398
-
Krakow, Pologne
- Sl0046 40502
-
Lublin, Pologne
- Sl0046 40151
-
Poznan, Pologne
- Sl0046 40044
-
Poznan, Pologne
- Sl0046 40090
-
Warsaw, Pologne
- Sl0046 40097
-
Warsaw, Pologne
- Sl0046 40098
-
Wroclaw, Pologne
- Sl0046 40397
-
Wroclaw, Pologne
- Sl0046 40481
-
-
-
-
-
Caguas, Porto Rico
- Sl0046 50671
-
-
-
-
-
Lima, Pérou
- Sl0046 60023
-
Lima, Pérou
- Sl0046 60009
-
-
-
-
-
Galati, Roumanie
- Sl0046 40382
-
-
-
-
-
Belgrade, Serbie
- Sl0046 40393
-
Belgrade, Serbie
- Sl0046 40461
-
Belgrade, Serbie
- Sl0046 40730
-
Novi Sad, Serbie
- Sl0046 40392
-
-
-
-
-
Taichung, Taïwan
- Sl0046 20113
-
Taichung, Taïwan
- Sl0046 20142
-
Taipei, Taïwan
- Sl0046 20095
-
Taiyuan, Taïwan
- Sl0046 20082
-
-
-
-
-
Prague, Tchéquie
- Sl0046 40066
-
-
-
-
Alabama
-
Birmingham, Alabama, États-Unis, 35294
- Sl0046 50140
-
-
Arizona
-
Avondale, Arizona, États-Unis, 85392
- Sl0046 50058
-
Glendale, Arizona, États-Unis, 85306
- Sl0046 50662
-
Phoenix, Arizona, États-Unis, 85032
- Sl0046 50052
-
Tucson, Arizona, États-Unis, 85704
- Sl0046 50328
-
-
California
-
Beverly Hills, California, États-Unis, 90210
- Sl0046 50383
-
La Palma, California, États-Unis, 90623-1730
- Sl0046 50275
-
San Leandro, California, États-Unis, 94578
- Sl0046 50316
-
-
Colorado
-
Denver, Colorado, États-Unis, 80230
- Sl0046 50339
-
-
Florida
-
Brandon, Florida, États-Unis, 33511
- Sl0046 50239
-
Gainesville, Florida, États-Unis, 32610
- Sl0046 50362
-
Miami, Florida, États-Unis, 33172
- Sl0046 50681
-
Ormond Beach, Florida, États-Unis, 32174
- Sl0046 50059
-
Plantation, Florida, États-Unis, 33324
- Sl0046 50324
-
Tampa, Florida, États-Unis, 33606
- Sl0046 50329
-
Tampa, Florida, États-Unis, 33618
- Sl0046 50698
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30303
- Sl0046 50368
-
-
Idaho
-
Idaho Falls, Idaho, États-Unis, 83404
- Sl0046 50240
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60616
- Sl0046 50699
-
-
Kentucky
-
Hopkinsville, Kentucky, États-Unis, 42240-1746
- Sl0046 50474
-
-
Louisiana
-
Lake Charles, Louisiana, États-Unis, 70605
- Sl0046 50285
-
New Orleans, Louisiana, États-Unis, 70112
- Sl0046 50660
-
-
Maryland
-
Hagerstown, Maryland, États-Unis, 21740
- Sl0046 50015
-
-
Michigan
-
Detroit, Michigan, États-Unis, 48201
- Sl0046 50219
-
-
Nevada
-
Las Vegas, Nevada, États-Unis, 89128
- Sl0046 50273
-
-
New York
-
Canton, New York, États-Unis, 13617
- Sl0046 50366
-
Manhasset, New York, États-Unis, 11030
- Sl0046 50264
-
New York, New York, États-Unis, 10032
- Sl0046 50334
-
-
North Carolina
-
Charlotte, North Carolina, États-Unis, 28211
- Sl0046 50238
-
-
Pennsylvania
-
Hershey, Pennsylvania, États-Unis, 17033
- Sl0046 50147
-
-
Tennessee
-
Jackson, Tennessee, États-Unis, 38305
- Sl0046 50001
-
-
Texas
-
Bellaire, Texas, États-Unis, 77401
- Sl0046 50738
-
Colleyville, Texas, États-Unis, 76034
- Sl0046 50418
-
-
West Virginia
-
Beckley, West Virginia, États-Unis, 25801
- Sl0046 50050
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- The participant could, in the opinion of the Investigator, benefit from long-term dapirolizumab pegol (DZP) treatment
- The participant completed one of the parent studies within 4 weeks prior to entry to this study
Exclusion Criteria:
- Study participant has any medical or psychiatric condition (including conditions due to neuropsychiatric systemic lupus erythematosus (SLE)) that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study. This includes study participants with a life-threatening condition or ongoing malignancies at the start of the study
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Dapirolizumab pegol
Subjects will receive dapriolizumab pegol throughout the Treatment Period. |
Subjects will receive dapirolizumab pegol at prespecified time-points.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence of treatment-emergent adverse events (TEAEs) during the study
Délai: From Baseline (Day 1) until Safety Follow-Up (up to Week 110)
|
Treatment-emergent adverse events (TEAEs) are any untoward medical incidence in a subject during administered study treatment, whether or not these events are related to study treatment. |
From Baseline (Day 1) until Safety Follow-Up (up to Week 110)
|
|
Incidence of serious treatment-emergent adverse events during the study
Délai: From Baseline (Day 1) until Safety Follow-Up (up to Week 110)
|
A serious treatment-emergent adverse event (serious TEAE) is any untoward medical occurrence that at any dose:
|
From Baseline (Day 1) until Safety Follow-Up (up to Week 110)
|
|
Incidence of treatment-emergent adverse events (TEAEs) leading to permanent dapirolizumab pegol discontinuation
Délai: From Baseline (Day 1) until Safety Follow-Up (up to Week 110)
|
Treatment-emergent adverse events (TEAEs) are any untoward medical incidence in a subject during administered study treatment, and leading to permanent drug discontinuation whether or not these events are related to study treatment. |
From Baseline (Day 1) until Safety Follow-Up (up to Week 110)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Achievement of prevention of severe BILAG flares (severe BILAG flare-free) through Week 24
Délai: Week 24
|
BILAG severe flare is defined as a new British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) Grade A since previous visit in any system due to individual items that are new or worse qualifying for the Grade A (Isenberg et al, 2011). Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index (Yee et al, 2010). |
Week 24
|
|
Achievement of prevention of severe BILAG flares (severe BILAG flare-free) through Week 52
Délai: Week 52
|
BILAG severe flare is defined as a new British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) Grade A since previous visit in any system due to individual items that are new or worse qualifying for the Grade A (Isenberg et al, 2011). Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index (Yee et al, 2010). |
Week 52
|
|
Achievement of prevention of severe BILAG flares (severe BILAG flare-free) through Week 104
Délai: Week 104
|
BILAG severe flare is defined as a new British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) Grade A since previous visit in any system due to individual items that are new or worse qualifying for the Grade A (Isenberg et al, 2011). Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index (Yee et al, 2010). |
Week 104
|
|
Achievement of LLDAS at ≥50% of all visits
Délai: From Baseline (Day 1) until End of Treatment (Week 104)
|
Low lupus disease activity state (LLDAS) is defined as:
|
From Baseline (Day 1) until End of Treatment (Week 104)
|
|
Achievement of BICLA response at Week 24
Délai: Week 24
|
A study participant is considered to be a BILAG 2004-based Composite Lupus Assessment (BICLA) responder if all of the following is fulfilled:
The parent studies Baseline will be used as reference point. |
Week 24
|
|
Achievement of BICLA response at Week 52
Délai: Week 52
|
A study participant is considered to be a BICLA responder if all of the following is fulfilled:
The parent studies Baseline will be used as reference point. |
Week 52
|
|
Achievement of BICLA response at Week 104
Délai: Week 104
|
A study participant is considered to be a BICLA responder if all of the following is fulfilled:
The parent studies Baseline will be used as reference point. |
Week 104
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: UCB Cares, 001 844 599 2273 (UCB)
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- SL0046
- 2019-003409-83 (Numéro EudraCT)
- U1111-1293-7098 (Autre identifiant: World Health Organization (WHO))
- 2023-506368-14 (Identificateur de registre: EU Clinical Trials)
- 2023 (Subvention/contrat des NIH des États-Unis)
- 2019 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
Délai de partage IPD
Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
Critères d'accès au partage IPD
Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- RSE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .